原发性硬化性胆管炎
胆管上皮细胞
炎症性肠病
炎症
医学
纤维化
癌症研究
代谢物
分泌物
内科学
生物
疾病
刺猬信号通路
免疫学
促炎细胞因子
胆道
内分泌学
病理生理学
下调和上调
药理学
细胞因子
肝病
信号
信号转导
胃肠道
肝纤维化
激酶
免疫系统
雷帕霉素的作用靶点
丙酸盐
基因敲除
肠道菌群
作者
Antonio Molinaro,Peder R. Braadland,Guido Carpino,Alba Carreras,Marios Nikolaidis,Petra Hanzely,Katharina R. Beck,Ahmad Hassan Ali,Lars Bossen,Anna Katharina Frank,Annika Lundqvist,Brian D. Juran,Diletta Overi,Lei Geng,Enya Amundsen-Isaksen,Henrik Mikael Reims,Ida Björk,Krzysztof Grzyb,Andreas Abildgaard,Trine Folseraas
标识
DOI:10.1038/s42255-026-01600-1
摘要
Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the bile ducts that can lead to biliary cancer and end-stage liver disease. PSC is associated with inflammatory bowel disease and an altered gut microbiota. However, the molecular mechanisms underlying gut-liver interactions in PSC remain poorly characterized. Here we show that the gut microbiota-derived metabolite imidazole propionate (ImP) is a disease driver in PSC. Individuals with PSC have higher circulating ImP levels than individuals with related conditions, and high ImP levels predict reduced survival in PSC. Cholangiocytes exposed to ImP show activated mammalian target of rapamycin complex 1 (mTORC1) signalling and secrete pro-inflammatory and pro-fibrogenic factors. Chronic administration of ImP to mice induces liver inflammation and fibrosis through a p38-dependent mechanism, upstream of mTORC1. We propose that chronic exposure to ImP induces cholangiocyte injury, which alone or in concert with other factors causes clinical worsening of PSC. Therefore, targeting ImP production or signalling may represent therapeutic avenues in PSC.
科研通智能强力驱动
Strongly Powered by AbleSci AI